Efficiency of Antegren

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Postby OddDuck » Fri Nov 12, 2004 8:53 am

I wasn't sure where to post this (or IF to post it), but I think I'll do it here.

When I wrote to the FDA with my concerns, I asked if they would be so kind as to just confirm receipt of my correspondence. I'm aware that the process they are in the middle of right now is highly confidential; therefore, I did not ask them specific questions nor did I press for information.

Well, just this morning I got confirmation from the FDA.

So, at the very least, they received it, and SOMEONE read it. That's all I was asking for.

It doesn't even matter if it was an automatically generated "response" or not. It's confirmation.

And I thank them for that. My faith in the FDA has just grown a hair.

Deb
User avatar
OddDuck
Contributing Author
 
Posts: 1040
Joined: Sat Jun 19, 2004 2:00 pm
Location: Tennessee

Advertisement

Postby HarryZ » Sun Nov 21, 2004 8:27 am

The following post was taken from the MS Foundation Forum. Beyond the possible name change to Antegren, I found it interesting that the FDA might insist that NAB testing is required for Antegren users. I thought that I had read somewhere that NABs weren't an issue with Antegren but it appears they very well may be.

Harry

______________________________________________

I went to the Texas Annual Meeting and Research Symposium today. Dr Edward Fox the medical director for the South Texas Chapter was one of the speakers. He got approval from the FDA to go ahead and give us an update on antegren. He was leaving the symposium to go to a lead researcher meeting on it.

He said the FDA has required them to change the name. It's name is too close to another drug and he doesn't know what the name will be. He is HOPEFULL and they are expecting it to be approved by the FDA this Tuesday, before Thanksgiving.

He still has questions about the insurance, but thinks that this will all be worked out in the next few months. They will have a hard time disallowing it because their data shows it to be at least 60% effective in reducing relaspes.

He said that 6% of people on it will develop neutralizing antibodies to what is now knowned as antegren and they will know as soon as 3-6 months, who those people are and they will have to be taken off. Because of the expense, people on this medication will have to be tested for this, but they are not sure who will do the testing.

The data looks good for short term but he couldn't say how it will work long term.

_____________________________________
User avatar
HarryZ
Family Elder
 
Posts: 2557
Joined: Tue May 25, 2004 2:00 pm
Location: London, ON, Canada

no benefit to tysabri + avonex?

Postby batpere » Wed Nov 24, 2004 5:54 am

Let's decipher the announcement.

66% reduction tysabri vs placebo
54% reduction tysabri+avonex vs placebo+avonex
.66 * .54 = .37

1 - .66 = .33

Is tysabri+avonex even less effective than tysabri alone?
Or would this not be statistically significant? It would after
all be from different patients.

Or am I flunking this story problem?
batpere
Family Member
 
Posts: 97
Joined: Thu Nov 11, 2004 3:00 pm
Location: dallas

Antegren (Tysabri) v. Beta Interferon v. Placebo

Postby MeadowStream » Wed Nov 24, 2004 2:11 pm

batpere,

I think the Sentinel data is a little confusing. The placebo IS beta interferon and the 54% reduction is Antegren (Tysabri) relative to beta interferon.

The Affirm data shows 66% reduction - Antegren (Tysabri) v. true placebo.

Furthermore, the Sentinel data is slightly confusing because the patient population is select: patients who have experienced exacerbations while already being treated with beta interferon.

Hope this helps,

MS
User avatar
MeadowStream
Family Member
 
Posts: 58
Joined: Sun Oct 17, 2004 2:00 pm

Previous

Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service